Skip to main content
    G

    GSK plc (GSK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $50.41
    -0.04 (-0.07%)

    Market Cap: $101.13B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    GSK plc (GSK) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    GSK trades at 10.5x trailing earnings and 2.3x sales. Its P/S of 2.3x is above its 5-year median of 2.0x. Its forward P/E is 10.0x. The median P/E across 9 similar companies is 19.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 5.0% higher over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.

    MultipleValue
    P/E (trailing)10.5x
    Forward P/E10.0x
    Price to sales2.3x
    Price to book4.1x
    Price to FCF11.4x
    PEGN/A
    FCF yield8.8%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is in line.

    MultipleCurrent5-year median10-year median
    P/S2.3x2.0xN/A
    P/B4.1x3.8x4.1x
    Medians of month-end values through Oct 2026: 56 to 60 months (5-year) and 114 months (10-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/S, its P/S ranged from 1.7x in 2024 to 2.3x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$49.042.3x4.5x
    2024$33.821.7x4.1x
    2023$37.062.0x3.5x
    2022$35.141.9x5.6x
    2021$55.13N/A3.3x
    2020$46.00N/A2.7x
    2019$58.742.3x5.9x
    2018$47.76N/A13.7x
    2017$44.34N/A40.4x
    2016$48.14N/A421.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    P/E history is shown only for companies that report in US dollars.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GSK

    What is GSK's forward P/E ratio?

    GSK has a forward P/E ratio of 10.0x.

    Is GSK stock overvalued?

    GNG's valuation label for GSK is Fairly valued. Its P/E of 10.5x compares with a median of 19.9x across 9 similar companies.

    What is GSK's price to sales ratio?

    GSK has a price to sales ratio of 2.3x.